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Abstract
Background: GIST patients often undergo GI-surgery. Previous studies have shown that imatinib and nilotinib
exposures were decreased in GIST patients with prior major gastrectomy. We investigated whether major gastrectomy
influences the exposure to sunitinib and its active metabolite SU12662.
Methods: Pharmacokinetic data from 305 GIST patients included in 4 phase I-III trials were analyzed. Patients were
subdivided into 6 groups according to their prior GI-surgery. Apparent clearance (CL/F) and dose-corrected steady-state
plasma exposures (AUC24,ss) of sunitinib and SU12662 were estimated using a population PK approach. ANCOVA was
performed to test for differences in AUC24,ss and CL/F between each surgery subgroup and controls.
Results: Major gastrectomy did not influence sunitinib or SU12662 exposure. The geometric mean of sunitinib and
SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n =8)
compared to controls (n =63) for sunitinib (931 ng*hr/mL (95%-CI; 676–1283) versus 1177 ng*hr/mL (95%-CI;
1097–1263); p <0.05) and SU12662 (354 ng*hr/mL (95%-CI; 174–720) versus 492 ng*hr/mL (95%-CI; 435–555); p <0.05).
No significant differences in exposure were observed in each of the other subgroups versus controls.
Conclusion: In contrast to previous results for imatinib and nilotinib, gastrectomy alone does not influence sunitinib or
SU12662 exposure. This should be taken into account for the treatment of gastrectomized GIST patients with TKIs. In
patients who had undergone both gastrectomy and small bowel resection, sunitinib and SU12662 exposures are
significantly, although clinically not relevantly, decreased.
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Background
Gastrointestinal stromal tumors (GISTs) are the most
common sarcoma of the gastrointestinal (GI) tract and
highly resistant to conventional chemotherapy [1]. In 2001,
imatinib was registered as first-line therapy for patients
with primary unresectable and/or metastatic GIST [2,3].
Thereafter in 2006, sunitinib was approved as second-line
treatment for patients intolerant or refractory to imatinib
therapy [4]. Recently, regorafenib was approved by the U.S.
FDA as third-line therapy for GISTafter failure of imatinib
and sunitinib [5]. With the introduction of imatinib, suniti-
nib and regorafenib, survival of patients with metastatic
GIST has substantially improved [4-6].
Imatinib Ctrough levels and total sunitinib exposure have
been reported to correlate with treatment benefit in pa-
tients with GIST [7,8]. However, GIST patients often have
an altered GI tract due to either resection of the primary
tumor or subsequent surgery for recurrence and/or metas-
tasis. Whether these alterations influence drug absorption
and thus exposure and clinical outcome of treatment, de-
pends on the physicochemical properties of the oral tyro-
sine kinase inhibitor given (Table 1).
A cross-sectional study in GIST patients treated with
imatinib revealed that Ctrough levels were significantly
lower in patients that previously had a major gastrec-
tomy compared to patients without gastric surgery [9].
Comparable results, relating decreased plasma drug ex-
posures with prior major gastrectomy, were seen for
GIST patients treated with nilotinib [10]. Since the solu-
bility of imatinib and nilotinib rapidly declines above
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tomized patients a decreased acid secretion may contribute
to a decreased solubility and thereby decreased absorption
of both TKIs [9-12]. Each segment of the gastrointestinal
tract has its own characteristic pH level; acidity declines
over the GI tract from the stomach (pH 1–3) to the small
intestine (pH 5–7) and the colon (pH 7–8) [13,14]. For
imatinib and nilotinib solubility and absorption therefore
rapidly decreases after the stomach [15]. This is further
supported by the relative short time to reach maximum
plasma concentration (Tmax) for these drugs; 2–4h o u r s
for imatinib and 3 hours for nilotinib [11,12]. Hence, due
to the physicochemical properties of imatinib and niloti-
nib, the stomach is essential for dissolution and absorption
of these TKIs.
For sunitinib however, solubility does not decline until
pH 6.8 [16]. This makes in theory the involvement of the
stomach less critical for dissolution and absorption of suni-
tinib. This is further supported by the relative broad sur-
face over which sunitinib is absorbed from the GI-tract,
reflected by a long time to reach maximum plasma con-
centration of sunitinib, e.g. 6–12 hours [16]. We postulated
that major gastrectomy would most likely not affect the
exposure to sunitinib and its active metabolite SU12662.
To confirm this hypothesis, we retrospectively investigated
the effect of GI resections on sunitinib and SU12662 ex-
posures in patients with GISTacross 4 different phase I-III
clinical trials. Our primary objective was to investigate the
effect of major gastrectomy; secondary objectives were to
determine the effect of other GI resections on sunitinib
exposure.
Methods
Patient selection
A total of 635 patients were treated with sunitinib in 4 dif-
ferent phase I/II, II, or III clinical trials that investigated
the safety, efficacy, and/or pharmacokinetics of sunitinib
in patients with GIST [17-20]. Of these 635 patients, a
total of 364 patients had pharmacokinetic (PK) samples
available which were included in population pharmacoki-
netic analysis. Out of these 364 patients (for sunitinib total
number of samples =3394 and for SU12662 total number
of samples =3410), a total of 305 patients had comprehen-
sive GI resection data available and were therefore eligible
for the present analysis.
Inclusion criteria in these trials were: a histopatholo-
gically confirmed diagnosis of metastatic or unresectable
GIST with progression on or toxicity of previous imatinib
therapy; age >18 years or between 20 to 75 years; ad-
equate hematologic, renal, liver and cardiac function; an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0 or 1; willingness and ability to comply
with scheduled visits, treatment plans, laboratory test, and
other study procedures.
Exclusion criteria in these trials were: current treatment
in another clinical trial or≤4 weeks prior to starting suni-
tinib, ≤ 2 weeks for imatinib therapy ; non recovery from
acute toxic effect of previous chemotherapy or imatinib;
a history of known brain metastases; any serious co-
morbidity; and pregnancy or breastfeeding.
All studies were done in accordance with Good Clinical
Practice and under the ethical principles established by
the Declaration of Helsinki. Each protocol was reviewed
and approved by the Institutional Review Board and in-
formed consent was obtained from each patient. The sub-
analysis on the existing dataset of Pfizer was requested by
the non-Pfizer affiliated authors of this manuscript and
was reviewed and granted by Pfizer.
Sunitinib pharmacokinetic data collection and
statistical analysis
Patients were treated with sunitinib in doses ranging from
25 mg to 75 mg once daily on 4/2 (4 weeks on treatment
followed by 2 weeks off treatment), 2/1 (2 weeks on treat-
ment followed by 1 week off treatment), 2/2 (2 weeks
on treatment followed by 2 weeks off treatment) or CDD
(continuous daily dosing) schedules. Blood samples for
pharmacokinetic assessment of sunitinib and its active
metabolite SU12662 were collected pre-dose or post-dose
on different days with details provided in Table 2. Blood
samples were collected in EDTA tubes and shortly after
collection centrifuged at 4°C for 10 minutes at 3500 rpm.
Plasma samples were separated and stored at −20°C or
lower until shipped. Shipment of samples was on dry ice
to Bioanalytical Systems Inc (West Lafayette, IN) where
they were stored at −20°C or lower until assayed within
the established stability window. For quantification a vali-
dated, sensitive and specific isocratic liquid chromato-
graphic tandem mass spectrometric (LC-MS/MS) method
in positive ionization mode was used [21].
Table 1 Physicochemical properties of imatinib, nilotinib and sunitinib
Drug MW (g/mol) pKa Solubility BCS class Reference
Imatinib 493.60 7.7 Freely soluble (100–1000 mg/ml) up to pH 5.5. Solubility declines at higher pH;
lowest solubility is 1 mg/ml.
II [11]
Nilotinib 565.98 2.1 and 5.4 Slightly soluble (1–10 mg/ml) at pH 1.0, very slightly soluble (0.1-1 mg/ml) in water,
at pH 3.0 and 3.0. Practically insoluble (<0.1 mg/ml) in buffer solutions of pH≥4.5
IV [12]
Sunitinib 398.47 9.0 25 mg/ml at pH 1.2-6.8. Solubility reduces at pH≥6.8 IV [16]
Abbreviation: BCS Biopharmaceutics Classification System, MW molecular weight.
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velop population PK models for sunitinib and SU012662
using Nonlinear Mixed Effect Modeling software (NON-
MEM; version 7.1.2), following exclusion of plasma sam-
ples with inadequate dosing records and those identified
to be extreme outliers (eg, 6 <Conditional Weighted Re-
sidual(CWRES) <−6). Sunitinib data were best described
by a two-compartment model with first-order order ab-
sorption with a lag time and first-order elimination.
Similarly, SU12662 data were best described by a two-
compartment model with first-order formation without
lag time and first-order elimination.
Patients were subdivided into 6 subgroups according to
their previous GI surgery: 1) Major gastrectomy (defined
as total or subtotal gastrectomy), 2) Partial gastrectomy, 3)
Small bowel resection, 4) Both gastrectomy (either partial
or (sub)total) and small bowel resection, 5) Colon resec-
tion, and 6) Controls with no prior surgery. Patients with
uncertain or unclear defined GI resections (n =59) were
excluded from analysis.
Following population PK analyses, the individual post-
hoc estimates for CL/F of sunitinib and SU12662 were
used to calculate steady-state total plasma exposures
(AUC24,ss) of sunitinib and SU12662 at 50 mg of sunitinib
for each individual patient, by dividing the dose (i.e.,
50 mg) by individual patient post-hoc CL/F estimate.
Thereafter, an analysis of covariance (ANCOVA) on log
transformed data was performed to test for significant dif-
ferences in AUC24,ss and CL/F of both sunitinib and
SU12662 between each surgical subgroup and control. Co-
variates previously identified by Houk et al. which were
initially included in the ANCOVA model were sex and
race for sunitinib CL/F, and sex, race, body weight and
ECOG performance status for SU12662 CL/F [22]. Within
the ANCOVA models, Multiple Comparisons with Con-
trol (i.e., MCC) using Dunnett’s test were performed and
significant increases in CL/F and decreases in AUC24,ss
were identified. For sunitinib and SU12662 CL/F the
difference was considered statistically significant (p≤
0.05), if the 95% lower bound for the difference from
controls on the log scale did not include zero. Con-
versely, for sunitinib and SU12662 AUC24,ss,i ft h e9 5 %
upper bound for the difference from the control, on the
log scale, did not include zero, the difference was con-
sidered statistically significant (p≤ 0.05). Subsequently,
previously identified covariates which were not statisti-
cally significant (p >0.05) within the ANCOVA model
were later removed from the ANCOVA models for suni-
tinib and SU12662. The number of observation for each
individual was added as an additional covariate to the
ANCOVA models to make sure it did not affect the final
ANCOVA models overall results and conclusions. All
statistical analyses were performed using S-Plus Version
8.0 (TIBCO Software Inc., Palo Alto, USA). The popula-
tion pharmacokinetic and statistical analysis on the
existing dataset was done by Pfizer Inc. Independent re-
viewers, blinded to the PK and patient data and not re-
lated to Pfizer subdivided the included patients into 6
groups according to their previous GI surgery.
Results
Patient characteristics
A total of 305 patients had both population PK parameter
estimates and comprehensive GI resection data available
and were therefore included in the descriptive statistics pre-
sented as well as in the analysis of covariance (ANCOVA)
models for sunitinib and SU12662. Of these patients, 45
underwent major gastrectomy (subgroup 1), 58 partial gas-
trectomy (subgroup 2), 118 small bowel resection (sub-
group 3), 8 both gastrectomy and small bowel resection
(subgroup 4) and 13 patients a colon resection (subgroup
5). Sixty-three patients served as controls and did not have
Table 2 Summary of characteristics of studies used for analyses
Study
number
Study
design
Population
(n)
a
Dosing schedule:
dose
Day(s) of PK sampling Time point(s) of sampling Reference(s)
RTKC-0511-013 Phase II 74 2/1: 50 mg Days 1, 14, 28 (only 4/2) of
Cycles 1, 2, and 3 (optional)
Pre-dose [19]
2/2: 25, 50, 75 mg On 1
st day of Cycle 1 and on last day of
Cycles 1 and 2: 0, 1, 4, 6, 8, 10, 12, 24, and
48 hr post-dose (10 and 12 hr optional) 4/2: 50 mg Day 1 of Cycles 4, 5 (optional),
and 6
A6181004 Phase III 179 4/2: 50 mg Days 1, 14, and 28 of Cycle 1;
Days 1 and 28 of Cycles 2
and beyond
Pre-dose [20]
A6181045 Phase I/II 33 4/2: 25, 50, 75 mg Phase I: Days 1, 2, 7, 14, 21,
a n d2 8o fC y c l e1
Pre-dose [18]
On Days 1 and 28 of Cycle 1 (Phase I Only):
0, 1, 2, 4, 6, 8, 10, 24 (Only Day 28) and 48
(Only Day 28) hr post-dose
Phase II: Days 1, 14, and 28 of
Cycles 1-4
A6181047 Phase II 19 CDD: 37.5 mg Day 1 of each cycle Pre-dose [17]
Abbreviations: 2/1 2 weeks on treatment followed by 1 week off treatment, 2/2 2 weeks on treatment followed by 2 weeks off treatment, 4/2 4 weeks on
treatment followed by 1 week off treatment, CDD continuous daily dosing, PK pharmacokinetics.
aNumber of subjects from each study contributing to the ANCOVA.
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cluding sex, age, bodyweight, ethnicity and ECOG perform-
i n gs t a t u sa r es h o w ni nT a b l e3p e rs u b g r o u p .
Effect of prior gastrointestinal surgery on sunitinib
pharmacokinetics
Sunitinib and SU12662 apparent clearance (CL/F) was not
increased in patients that previously had a major gastrec-
tomy. Consequently, the geometric mean of sunitinib and
SU12662 AUC0-24hr were not decreased in patients with a
major gastrectomy, compared to patients in the control sub-
group for sunitinib (1171 ng*hr/mL versus 1177 ng*hr/mL;
p >0.05) and SU12662 (520 ng*hr/mL versus 492 ng*hr/mL
p >0.05) (Table 4 and Figure 1).
A significant increase in apparent clearance (CL/F) of
sunitinib and SU12662 was seen in patients that had
undergone both gastrectomy and small bowel resection
relative to the controls. The geometric mean of CL/F for
sunitinib and SU12662 was increased by 26% and 39% in
subgroup 4, patients with both gastrectomy and small
bowel resection, compared to those in the control sub-
group for sunitinib (53.7 L/hr versus 42.5 L/hr; p≤0.05)
and for SU12662 (29.7 L/hr versus 21.4 L/hr; p≤0.05), re-
spectively. No statistically significant (p >0.05) increases
in apparent clearance for each of the other subgroups
from controls were observed (Table 4 and Figure 1).
Consequently, a decreased total plasma exposure
(AUC24,ss) to sunitinib and SU12662 was seen in patients
that had undergone both gastrectomy and small bowel re-
section. The geometric mean of total plasma exposure
(AUC24,ss) to sunitinib and SU12662 was 21% and 28%
lower in subgroup 4, patients that underwent both gas-
trectomy and small bowel resection, compared to those in
the control subgroup sunitinib (931 ng*hr/mL versus
1177 ng*hr/mL; p≤ 0.05) and for SU12662 (354 ng*hr/
mL versus 492 ng*hr/mL; p ≤ 0.05), respectively. No sta-
tistically significant (p >0.05) decreases in total plasma
exposures for each of the other subgroups compared to
controls were observed (Table 4 and Figure 1).
Discussion
This study shows that major gastrectomy did not affect su-
nitinib or SU12662 plasma exposures in patients with
GIST. This is in contrast to prior data regarding the impact
of gastrectomy on both imatinib and nilotinib exposure
[9,10]. Sunitinib and SU12662 exposures were however
significantly decreased in patients who had previously
undergone both gastrectomy and small bowel resection, al-
though this observation was in a small subgroup of pa-
tients. All other types of GI resections studied showed no
impact on sunitinib or SU12662 pharmacokinetics.
The results from this study support our hypothesis that
the influence of GI resections on TKI exposure depends on
two variables: the specific physicochemical properties of the
TKI given and the part of the GI tract that has undergone
resection. So although most TKIs exhibit pH-dependent
solubility, small differences in their physicochemical prop-
erties (e.g. declined solubility in pH conditions higher than
pH 5.5 for imatinib versus 6.8 for sunitinib) may cause
great differences in the impact of gastrectomy on their GI
solubility and absorption. In addition, the absorption char-
acteristics of a drug under normal conditions [i.e. whether
it is absorbed throughout the GI tract (e.g. sunitinib) or
whether it is mainly absorbed through the stomach and the
upper part of the small intestine (e.g. imatinib)] may affect
the extent to which site specific GI resections can decrease
the GI availability (Fgut) and subsequently the bioavailability
(F =Fgut*Fhepatic) of a drug. The finding that imatinib
Table 3 Patient characteristics for each past GI surgery subgroup
Major gastrectomy
(n = 45)
Partial gastrectomy
(n =58 )
Small bowel
resection (n = 118)
Combination of
gastrectomy and
small bowel resection
(n =8 )
Colon resection
(n =13)
Controls
(n =63)
Sex, n (%)
Male 30 (66.7%) 35 (60.3%) 75 (63.6%) 6 (75%) 9 (69.2%) 40 (63.5%)
Female 15 (33.3%) 23 (39.7%) 43 (36.4%) 2 (25%) 4 (30.8%) 23 (36.5%)
Age (years)* 56 (36–77) 57 (28–79) 53 (23–81) 49 (45–54) 68 (50–84) 58 (36–84)
Bodyweight (kg)* 65 (40–100) 70 (39–121) 71 (40–140) 64 (45–139) 80 (56–114) 74 (44–137)
Race, n (%)
Non-Asian 37 (82.2%) 52 (89.7%) 94 (79.7%) 7 (87.5%) 12 (92.3%) 59 (93.7%)
Asian 8 (17.8%) 6 (10.3%) 24 (20.3%) 1 (12.5%) 1 (7.7%) 4 (6.3%)
ECOG performing
status, n (%)
≤ 1 42 (93.3%) 58 (100%) 116 (98.3%) 8 (100%) 13 (100%) 62 (98.4%)
≥ 2 3 (6.7%) 0 (0%) 2 (1.7%) 0 (0%) 0 (0%) 1 (1.6%)
*Data are presented as median values with lower and upper limit.
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proton pump inhibitor omeprazole somewhat contradicts
our hypothesis considering reduced solubility [23]. How-
ever, 40 mg omeprazole only increases the gastric pH to 4.6
which is still an adequate level for imatinib to freely dissolve
[24]. Major gastrectomy might result in a further rise in pH
equally to that of the small intestines and this therefore
could interfere with imatinib dissolution.
Currently, the approved and accepted first line treat-
ment for GIST is imatinib [11]. The stomach is the most
common primary site for GIST (~60%), and a proportion
of these patients will therefore undergo major gastrectomy
procedures prior to systemic imatinib therapy for metasta-
sis [25]. Imatinib Ctrough levels in ~80% of the gastrecto-
mized patients were reported to be below 1100 ng/mL
which has been correlated to shorter progression free sur-
vival (PFS) [7,9]. In addition, increasing the imatinib dose
might not result in an increased exposure due to the lim-
ited solubility of imatinib in a patient with limited gastric
physiology. By measuring plasma concentrations in pa-
tients with prior major gastrectomy, a decreased exposure
to imatinib could be identified early in treatment, prior to
development of clinical drug failure. Sunitinib is currently
approved and accepted as the second line treatment for
GIST patients and also for sunitinib a relationship be-
tween systemic exposure and efficacy has been demon-
strated before [8,16]. The results from this present study
show that sunitinib exposure is, in contrast to the results
for imatinib, not decreased in gastrectomized patients.
These findings should be taken into account for the
treatment of gastrectomized GIST patients with TKIs.
Hypothetically, gastrectomized patients have less and/or
shorter treatment benefit from first-line imatinib therapy
due to decreased imatinib plasma levels. Yet, these
patients theoretically have a high chance of treatment
benefit from second-line sunitinib therapy. However, fur-
ther prospective research to investigate this hypothesis
and whether there is a difference in clinical outcome be-
tween gastrectomized patients treated with imatinib or su-
nitinib is needed.
The results from this present analysis also show that pa-
tients who had undergone both gastrectomy and small
bowel resection did have statistically significantly (p≤
0.05) lower sunitinib and SU12662 exposures, which is an
extension of prior data showing such effects of combined
surgery on plasma exposure of both imatinib and nilotinib
[9,10]. An effect of both gastrectomy and small bowel re-
section on the exposure to all three studied TKIs and
other drugs is not surprising, since resections of large por-
tions of the GI tract will significantly reduce the absorp-
tion surface available. Houk et al. showed that patients
with GISTand a sunitinib AUCss >600 ng*hr/mL had lon-
ger time to progression (TTP) and overall survival (OS)
[8]. The patients with a combined gastrectomy and small
bowel resection in our study had an average sunitinib ex-
posure of 931 ng*hr/mL and none of the patients in this
subgroup had a sunitinib exposure <600 ng*hr/mL. So al-
though patients with both a gastrectomy and small bowel
resection in this study had a statistically significant (p≤
0.05) decrease in sunitinib and SU12662 exposure, this de-
crease does not appear to be clinically relevant.
Hypothetically, the extent of small bowel resection will
be critical for the remaining absorption surface and
whether and to what extent sunitinib exposure is affected
or not. Unfortunately, the length of resected intestine was
not registered in the database used for this retrospective
study, which limits the ability to analyze this variable.
Measuring plasma concentrations of sunitinib could be
Table 4 Sunitinib and SU12662 CL/F and AUC24,ss estimates for each past GI surgery subgroup
Parameter Past GI surgery subgroup
Major gastrectomy
(n = 45)
Partial gastrectomy
(n = 58 )
Small bowel
r e s e c t i o n( n=1 1 8 )
Combination of
gastrectomy and
small bowel resection
(n =8 )
Colon resection
(n = 13)
Controls
(n =63)
Number of PK
samples per subject,
median (range)
7( 1 –32) 9 (1–38) 7 (1–35) 10 (2–35) 13 (2–30) 7 (1–37)
Sunitinib
AUC24,ss
(ng*hr/mL)
1171 (1099–1248) 1294 (1228–1365) 1194 (1141–1250) 931 (676–1283)* 1325 (1109–1583) 1177 (1097–1263)
CL/F (L/hr) 42.7 (40.1 - 45.5) 38.6 (36.6 - 40.7) 41.9 (40.0 - 43.8) 53.7 ( 39.0 - 74.0)* 37.7 (31.6 - 45.1) 42.5 (39.6 - 45.6)
SU12662
AUC24,ss
(ng*hr/mL)
520 (474–571) 567 (522–617) 492 (458–529) 354 (174–720)* 597 (457–779) 492 (435–555)
CL/F (L/hr) 20.2 (18.4 - 22.1) 18.5 (17.0 - 20.1) 21.4 (19.9 - 23.0) 29.7 (14.6 - 60.4)* 17.6 (13.5 - 23.0) 21.4 (18.9 - 24.1)
Abbreviations: AUC24,ss Area Under the Concentration-time curve from time zero to 24 hours post-dose at steady state, CL/F apparent clearance,
PK pharmacokinetic.
Data are presented as geometric mean (95% CI) unless stated otherwise. *Significantly different compared to controls (p < 0.05).
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large resection of the GI tract to identify those that do
have a clinically relevant decreased sunitinib exposure. In
clinics where the measurement of sunitinib plasma con-
centration is not feasible, an alternative and practical ap-
proach could be to gradually increase the dose based on
the individual patient safety and tolerability. The relatively
small number of patients who underwent a combined
gastrectomy and small bowel resection (n =8) can be con-
sidered as a limitation of this present study. Therefore, the
results in this subgroup of patients should be interpreted
with caution and need to be verified in a larger group of
patients with extended GI resections.
It is generally assumed that for most weakly basic
drugs, the dissolution process is often the rate-limiting
step for absorption of these drugs from the GI tract.
Figure 1 Exposures in patients with different GI resections. a) Sunitinib exposure. b) SU12662 exposure. Abbreviations: SU = sunitinib;
M1 = SU12662. Legend: 1 = Major gastrectomy; 2 = Partial gastrectomy; 3 = Small bowel resection; 4 = Combination of gastrectomy and small
bowel resection; 5 = Colon resection; 6 = Controls with no prior surgery.
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are other variables within the GI tract that determine the
rate and extent of dissolution including the fluid volume
available for dissolution that is added in the stomach, gas-
tric motility and the maximum dose strength. Also the
maximum dose strength is rather different between ima-
tinib, nilotinib and sunitinib. Imatinib and nilotinib are
dosed at 400–800 mg a day compared to sunitinib which
is dosed at 25–50 mg a day. This could be an additional
explanation why sunitinib exposure is not influenced by
gastrectomy whereas imatinib and nilotinib exposure are.
Apparently, pH and dosage rather than fluid volume and
gastric motility is of influence on the absorption of TKIs.
An alternative pre-clinical explanation for the found differ-
ences is the removal due to gastrectomy of transporters
that facilitate the gastric absorption of TKIs, whereby ima-
tinib might depend more on this transporter for absorp-
tion than sunitinib does [26,27].
Conclusion
In conclusion, major gastrectomy alone does not influence
exposure to sunitinib or its active metabolite SU12662,
which is contrary to previous results for imatinib and nilo-
tinib. This should be taken into account for the treatment
of gastrectomized GIST patients withTKIs. Patients with a
combined gastrectomy and small bowel resection had a
statistically significantly, though clinically not relevant, de-
creased plasma exposure to sunitinib and SU12662 which
in theory might depend on the length of intestine resected.
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